Michael Barbella, Managing Editor03.23.24
Salutations and sayonaras captured the public interest on MPO's website this past week, with a merger, sale, and product authorizations driving most traffic.
Johnson Matthey bid farewell to its Medical Device Components and Battery Systems businesses as part of a broader restructuring that began two years ago. Montagu Private Equity is forking out $700 million in cash for the company's Medical Device Components division, which produces medical device components made from precious metal alloys and nitinol. The business has a global customer based and manufacturing sites in the United States, Mexico, and Australia. Johnson Matthey this week also concluded the divestment of its Battery Systems business, first announced in May 2022.
Johnson Matthey's business divestment was somewhat offset by word of Titan Medical's merger with Toronto-based Conavi Medical. Titan will acquire all issued and outstanding Conavi shares; in exchange, Conavi shareholders will be issued common shares of Titan. The transaction will constitute a reverse takeover of Titan.
Product authorizations favored by MPO cybervisitors included an automated insulin delivery system from Sequel Med Tech and a next-generation robotic surgical system from Intuitive Surgical.
Sequel Med Tech's partner DEKA R&D earned FDA 510(k) clearance for its twist automated insulin delivery (AID) system powered by Tidepool. The twiist AID system is the first drug delivery system that directly measures the volume and flow of insulin delivered with every micro-dose, according to the company. It’s cleared for type 1 diabetes patients aged 6 and up and can address individual dosing needs.
Intuitive, meanwhile, gained FDA 510(k) clearance for da Vinci 5, its next-generation multiport robotic surgical system featuring new surgeon controllers and vibration/tremor controls. da Vinci 5 also has integrated insufflation, an electrosurgical unit, and an optimized user interface with settings that are accessible by the broader surgical team and by the surgeon directly from the head-in menu.
Johnson Matthey bid farewell to its Medical Device Components and Battery Systems businesses as part of a broader restructuring that began two years ago. Montagu Private Equity is forking out $700 million in cash for the company's Medical Device Components division, which produces medical device components made from precious metal alloys and nitinol. The business has a global customer based and manufacturing sites in the United States, Mexico, and Australia. Johnson Matthey this week also concluded the divestment of its Battery Systems business, first announced in May 2022.
Johnson Matthey's business divestment was somewhat offset by word of Titan Medical's merger with Toronto-based Conavi Medical. Titan will acquire all issued and outstanding Conavi shares; in exchange, Conavi shareholders will be issued common shares of Titan. The transaction will constitute a reverse takeover of Titan.
Product authorizations favored by MPO cybervisitors included an automated insulin delivery system from Sequel Med Tech and a next-generation robotic surgical system from Intuitive Surgical.
Sequel Med Tech's partner DEKA R&D earned FDA 510(k) clearance for its twist automated insulin delivery (AID) system powered by Tidepool. The twiist AID system is the first drug delivery system that directly measures the volume and flow of insulin delivered with every micro-dose, according to the company. It’s cleared for type 1 diabetes patients aged 6 and up and can address individual dosing needs.
Intuitive, meanwhile, gained FDA 510(k) clearance for da Vinci 5, its next-generation multiport robotic surgical system featuring new surgeon controllers and vibration/tremor controls. da Vinci 5 also has integrated insufflation, an electrosurgical unit, and an optimized user interface with settings that are accessible by the broader surgical team and by the surgeon directly from the head-in menu.